Risk factors and characteristics of extent progression in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 15, Issue 9, 2009, Pages 1320-1325

  Etchevers, María Josefina ^a   Aceituno, Montserrat ^b   García Bosch, Orlando ^b   Ordás, Ingrid ^b   Sans, Miquel ^b   Ricart, Elena ^b   Panés, Julián ^b  

^a HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Disease severity; Prognosis; Sclerosing cholangitis; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; STEROID; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DESCENDING COLON; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL SURGERY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCLEROSING CHOLANGITIS; STEROID THERAPY; ULCERATIVE COLITIS; INCIDENCE; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 70449715454     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20897     Document Type: Article

References (34)

1. Hoi O, Wolters FL, Moum B, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507-515. (Pubitemid 46298736)
2. Sicilia B, Vicente R, Gomollón F, et al. Ulcerative pancolitis predicts the need for colectomy: study of an incident cohort of patients with ulcerative colitis in Aragón (Spain). Gastroenterol Hepatol. 2005;28:55-59. (Pubitemid 40293045)
3. Loftus EV Jr. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am. 2006;35:517-531. (Pubitemid 44307577)
4. Triantafillidis J, Emmanoudilis A, Barbatzas C, et al. Ulcerative colitis in Greece: clinicoepidemiological data, course and prognostic factors in 413 consecutive patients. J Clin Gastroenterol. 1998;27:204-210. (Pubitemid 28495837)
5. Moum B, Ekbom A, Elgjo K, et al. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol. 1999;94:1564-1569. (Pubitemid 29260447)
6. Park SH, Kim YM, Yang S-K, et al. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis. 2007;13:278-283. (Pubitemid 46465908)
7. Henriksen M, Jahnsen J, Moum B, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN Study). Inflamm Bowel Dis. 2006;12:543-550. (Pubitemid 43977734)
8. Meucci G, Vecchi M, de Franchis R, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Am J Gastroenterol. 2000;95:469-473. (Pubitemid 30106178)
9. Chatzicostas C, Roussomoustakaki M, Kouroumalis E, et al. Factors associated with disease evolution in Greek patients with inflammatory bowel disease. BMC Gastroenterol. 2006;6:21. (Pubitemid 44322270)
10. Ayres RC, Guillen CD, Allan RN, et al. Progression of ulcerative proctosigmoiditis: incidence factors influencing progression. Eur J Gastroenterol Hepatol. 1996;8:555-558.
11. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38:1137-1146.
12. Langholz E, Munkholm P, Binder V, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260-266. (Pubitemid 126422244)
13. Samuelsson SM, Ekbom A, Adami HO, et al. Risk factors for extensive ulcerative colitis and ulcerative proctitis: a population based case-control study. Gut. 1991;32:1526-1530.
14. Pierik M, Joossens S, Vermiere S, et al. Toll-like receptor-1, -2 and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis. 2006;12:1-8. (Pubitemid 43032444)
15. Bru C, Sans M, Panés J, et al. Hydrocolonic sonography for evaluating inflammatory bowel disease. AJR Am J Roentgenol. 2001;177:99-105.
16. Triantafillidis JK, Emmanouilidis A, Argyros N, et al. Ulcerative colitis in the elderly: clinical patterns and outcome in 51 Greek patients. J Gastroenterol. 2001;36:354-355.
17. Tobin MV, Logan RF, Gilmore IT, et al. Cigarette smoking and inflammatory bowel disease. Gastroenterology. 1987;93:316-321. (Pubitemid 17097599)
18. Corrao G, Tragnone A, Mansi C, et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control-study. Int J Epidemiol. 1998;27:397-404. (Pubitemid 28336965)
19. Abraham N, Selby W, Solomon M, et al. Is smoking an indirect risk factor for development of ulcerative colitis? An age- and sex-matched case control study. J Gastroenterol Hepatol. 2003;18:139-146. (Pubitemid 36349858)
20. Rodríguez García LA, González Pérez A, Wallander MA, et al. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther. 2005;22:309-315.
21. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther. 2005;921-931. (Pubitemid 40529727)
22. Beaugerie L, Massot N, Cosnes J, et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol. 2001;96:2113-2116. (Pubitemid 32660906)
23. Odes HS, Fich A, Gilat T, et al. Effects of current cigarette smoking on clinical course of Crohn's disease and ulcerative colitis. Dig Dis Sci. 2001;46:1717-1721. (Pubitemid 32727104)
24. Andersson RE, Olaison G, Ekbom A, et al. Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001;344:808-817 (Pubitemid 32222158)
25. Hallas J, Gaist D, Sorensen HT. Does appendectomy reduce the risk of ulcerative colitis? Epidemiology. 2004;15:173-178. (Pubitemid 40416971)
26. Radford-Smith GL, Edwards JE, Florin THJ, et al. Protective role of appendectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut. 2002;51:808-813.
27. Florin THJ, Pandeya N, Radford-Smith GL. Epidemiology of appendectomy in primary cholangitis and ulcerative colitis: its influence on the clinical behavior of these diseases. Gut. 2004;53:973-979. (Pubitemid 38824155)
28. Selby WS, Griffin S, Solomon MJ, et al. Appendectomy protects against the development of ulcerative colitis but does not affect its course. Am J Gastroenterol. 2002;97:2834-2838. (Pubitemid 35265436)
29. Hallas J, Gaist D, Sorensen HT, et al. Appendectomy has no benefitial effect on admission rates in patients with ulcerative colitis. Gut. 2004;53:351-354. (Pubitemid 38241328)
30. Pica R, Paoluzi OA, Paoluzi P., et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis. 2004;10:731-736. (Pubitemid 39545217)
31. Lakatos L, Pandur T, Lakatos PL et al. Association of extra intestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9:2300-2307. (Pubitemid 37321464)
32. Monsen U, Sorstad J, Johansson C, et al. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol. 1990;85:711-716. (Pubitemid 20185180)
33. Broomé U, Löfberg R, Veress B, et al. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum. 1995;38:1301-1305.
34. Loftus EV Jr, Harewood GC, Sandborn WJ, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91-96. (Pubitemid 40007225)